News
VYTORIN the cholesterol-lowering medicine from Merck
In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck (known as MSD outside the US and Canada), VYTORIN 10/20 mg reduced the incidence of first major vascular events -- defined as non-fatal heart attacks or cardiac...
News
Antares Pharma Announces Next Generation of Auto-Injector Design
Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares' new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater...
News
Pfizer Announces Positive Phase 3 Trial Results for Axitinib
Pfizer Inc.announced that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when...
News
Britannia innovates to provide Lifestyle Management Solutions for Diabetes
Britannia Industries Limited, one of India’s leading Food companies, has over the last 2 years demonstrated significant initiatives in the Health and Wellness space. Its work spans from creating products rich in nutrition to building awareness and advocacy for...
News
Eisai Inc. Received U.S Food and Drug Administration for Eisai’s Halaven Injection
Eisai Inc. announced that the United States Food and Drug Administration (FDA) has approved Halaven™ (eribulin mesylate) Injection for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment...
News
MorphoSys Launches New Antibody Technology
MorphoSys AG has launched a novel antibody optimization platform called arYla. The company plans to use arYla to accelerate antibody optimization, with the goal of generating superior therapeutic and diagnostic candidates faster and more cost-effectively than is currently possible,...
News
Biomoda Selects Quintiles To Refine Lung Cancer Tests
Biomoda, Inc. has allied with Quintiles Global Central Laboratories to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath-stained cells to detect early stage lung cancer. Biomoda’s...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
